SCHEMBL18990167

SCHEMBL18990167

CCOC(=O)C1CCCC(Nc2nc3c(c(=O)n(Cc4ccc(Cl)c(Cl)c4)c(=O)n3C)n2CCC(N)=O)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTHFD2 P13995 1/20 0.56
▸ PDE5A O76074 7/20 0.48
▸ MAPT P10636 4/20 0.47
▸ TP53 P04637 3/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ STAT6 P42226 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ TSHR P16473 3/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18990797 0.94 MTHFD2 (0.58) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18990105 0.93 MTHFD2 (0.58) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18990116 0.92 MTHFD2 (0.58) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18989636 0.91 MTHFD2 (0.60) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18991063 0.90 MTHFD2 (0.57) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18990606 0.89 MTHFD2 (0.54) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18990010 0.89 MTHFD2 (0.54) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18990084 0.87 MTHFD2 (0.53) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18989681 0.87 MTHFD2 (0.59) MTHFD2PDE5AMAPTTP53SMN1; SMN2
SCHEMBL18989793 0.86 MTHFD2 (0.73) MTHFD2PDE5AMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2018-12-27 — — US disclosed
EP-3389664-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF Raze Therapeutics Inc. (US) 2018-10-24 — — EP disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 MTHFD2 1/4885PDE5A 562/4885MAPT 1028/4885
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 MTHFD2 1/4885PDE5A 562/4885MAPT 1028/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 MTHFD2 1/4885PDE5A 562/4885MAPT 1028/4885
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 MTHFD2 1/4885PDE5A 562/4885MAPT 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback